Pointing to antiplatelet drugs as potential therapeutic targets in CAA and AD treatment, it has been revealed that the P2Y12 receptor antagonist clopidogrel inhibits Aβ aggregation in platelet cultures, which was accompanied by reduction in clusterin in the circulation and a diminished incidence of CAA in a transgenic mice AD model [60]. Here, CLU is linked to Alzheimer disease.